Abstract
Purpose: We aimed to investigate the prophylactic effects of trimetazidine against contrast induced nephropathy (CIN) in rat kidney tissues. Methods: 28 wistar rats were divided into 4 groups of 7 rats each (control (C), contrast media (CM), trimetazidine (TMZ), trimetazidin + contrast media groups (TMZ+CM).Second day,contrast media (Omnipaque 300 mg I/ml) was administered at a single dose of 10 ml/kg into the tail vein. The administration of TMZ solution (10 mg/kg/day) was done on the second, third, and fourth days. After sacrification, the left kidney was dissected for measuring the SOD, CAT, GSH and MDA levels. The histopathological evaluation of the right kidney was performed by a pathologist using a semiquantitative scale of 0 to 3. Results: All histopathological scores were significantly higher in the CM group as compared to other groups.Moreover the scores of the CM+TMZ and C groups were not statistically different (Table 1).CM group, had significantly higher levels of MDA compared to the C group (562,82±38,15 versus 419,15±49,01 nmol/mg protein) (p 0.05).CM group had significantly lower levels of SOD as compared to C,CM+TMZ and TMZ groups (2,54±0,26 versus 3,73±0,42, 3,72±0,37 and 3,87±0,20 U/mg protein respectively) (p<0.05). View this table: Table 1 Conclusion: To the best of our knowledge, this study, for the first time,histopathologically demonstrated the effectiveness of TMZ for the prevention of CIN.Antioxidant properties of TMZ might have contributed to these findings.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.